|
code |
description |
|
0001F |
Heart failure assessed (includes assessment of all the following components)(CAD, HF)1: Blood pressure measured (2000F)1 Level of activity assessed (1003F)1 Clinical symptoms of volume overload (excess) assessed (1004F)1 Weight, recorded (2001F)1 Clinical signs of volume overload (excess) assessed (2002F)1 |
|
0005F |
Osteoarthritis assessed (OA)1 Includes assessment of all the following components: Osteoarthritis symptoms and functional status assessed (1006F)1 Use of anti-inflammatory or over-the-counter (OTC) analgesic medications assessed (1007F)1 Initial examination of the involved joint(s) (includes visual inspection, palpation, range of motion) (2004F)1 |
|
0012F |
Community-acquired bacterial pneumonia assessment (includes all of the following components) (CAP)1: Co-morbid conditions assessed (1026F)1 Vital signs recorded (2010F)1 Mental status assessed (2014F)1 Hydration status assessed (2018F)1 |
|
0016T |
Destruction of localized lesion of choroid (eg, choroidal neovascularization), transpupillary thermotherapy |
|
0017T |
Destruction of macular drusen, photocoagulation |
|
0018T |
Delivery of high power, focal magnetic pulses for direct stimulation to cortical neurons |
|
0019T |
Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, low energy |
|
0026T |
Lipoprotein, direct measurement, intermediate density lipoproteins (IDL) (remnant lipoproteins) |
|
0027T |
Endoscopic lysis of epidural adhesions with direct visualization using mechanical means (eg, spinal endoscopic catheter system) or solution injection (eg, normal saline) including radiologic localization and epidurography |
|
0028T |
Dual energy x-ray absorptiometry (DEXA) body composition study, one or more sites |
|
0029T |
Treatment(s) for incontinence, pulsed magnetic neuromodulation, per day |
|
0030T |
Antiprothrombin (phospholipid cofactor) antibody, each IG class |
|
0031T |
Speculoscopy |
|
0032T |
Speculoscopy; with directed sampling |
|
0041T |
Urinalysis infectious agent detection, semi-quantitative analysis of volatile compounds |
|
0042T |
Cerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time |
|
0043T |
Carbon monoxide, expired gas analysis (e.g., etcoc/hemolysis breath test) |
|
0046T |
Catheter lavage of a mammary duct(s) for collection of cytology specimen(s), in high risk individuals (GAIL risk scoring or prior personal history of breast cancer), each breast; single duct |
|
0047T |
Catheter lavage of a mammary duct(s) for collection of cytology specimen(s), in high risk individuals (GAIL risk scoring or prior personal history of breast cancer), each breast; each additional duct |
|
0048T |
Implantation of a ventricular assist device, extracorporeal, percutaneous transseptal access, single or dual cannulation |
|
0049T |
Prolonged extracorporeal percutaneous transseptal ventricular assist device, greater than 24 hours, each subsequent 24 hour period (List separately in addition to code for primary procedure) |
|
0050T |
Removal of a ventricular assist device, extracorporeal, percutaneous transseptal access, single or dual cannulation |
|
0051T |
Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy |
|
0052T |
Replacement or repair of thoracic unit of a total replacement heart system (artificial heart) |
|
0053T |
Replacement or repair of implantable component or components of total replacement heart system (artificial heart), excluding thoracic unit |
|
0054T |
Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on fluoroscopic images (List separately in addition to code for primary procedure) |
|
0055T |
Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on CT/MRI images (List separately in addition to code for primary procedure) |
|
0056T |
Computer-assisted musculoskeletal surgical navigational orthopedic procedure, image-less (List separately in addition to code for primary procedure) |
|
0058T |
Cryopreservation; reproductive tissue, ovarian |
|
0059T |
Cryopreservation; oocyte(s) |
|
0060T |
Electrical impedance scan of the breast, bilateral (risk assessment device for breast cancer) |
|
0061T |
Destruction/reduction of malignant breast tumor including breast carcinoma cells in the margins, microwave phased array thermotherapy, disposable catheter with combined temperature monitoring probe and microwave sensor, externally applied microwave energy, including interstitial placement of sensor |
|
0062T |
Percutaneous intradiscal annuloplasty, any method except electrothermal, unilateral or bilateral including fluoroscopic guidance; single level |
|
0063T |
Percutaneous intradiscal annuloplasty, any method except electrothermal, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to 0062T for primary procedure) |
|
0064T |
Spectroscopy, expired gas analysis (e.g., nitric oxide/carbon dioxide test) |
|
0065T |
Ocular photoscreening, with interpretation and report, bilateral |
|
0068T |
Acoustic heart sound recording and computer analysis; with interpretation and report |
|
0069T |
Acoustic heart sound recording and computer analysis; acoustic heart sound recording and computer analysis only |
|
0070T |
Acoustic heart sound recording and computer analysis; interpretation and report only |
|
0071T |
Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue |
|
0072T |
Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue |
|
0073T |
Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session |
|
0074T |
Online evaluation and management service, per encounter, provided by a physician, using the Internet or similar electronic communications network, in response to a patient's request, established patient |
|
0077T |
Implanting and securing cerebral thermal perfusion probe, including twist drill or burr hole, to measure absolute cerebral tissue perfusion |
|
0088T |
Submucosal radiofrequency tissue volume reduction of tongue base, one or more sites, per session (ie, for treatment of obstructive sleep apnea syndrome) |
|
0089T |
Actigraphy testing, recording, analysis and interpretation (minimum of three-day recording) |
|
0090T |
Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression) cervical; single interspace |
|
0092T |
Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression) cervical; each additional interspace (List separately in addition to code for primary procedure) |
|
0093T |
Removal of total disc arthroplasty, anterior approach cervical; single interspace |
|
0095T |
Removal of total disc arthroplasty, anterior approach cervical; each additional interspace (List separately in addition to code for primary procedure) |
|
0096T |
Revision of total disc arthroplasty, anterior approach cervical; single interspace |
|
0098T |
Revision of total disc arthroplasty, anterior approach cervical; each additional interspace (List separately in addition to code for primary procedure) |
|
0099T |
Implantation of intrastromal corneal ring segments |
|
0100T |
Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy |
|
0101T |
Extracorporeal shock wave involving musculoskeletal system, not otherwise specified |
|
0102T |
Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle |
|
0103T |
Holotranscobalamin quantitative |
|
0104T |
Inert gas rebreathing for cardiac output measurement; during rest |
|
0105T |
Inert gas rebreathing for cardiac output measurement; during exercise |
|
0106T |
Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation |
|
0107T |
Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation |
|
0108T |
Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia |
|
0109T |
Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia |
|
0110T |
Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation |
|
0111T |
Long-chain (c20-22) omega-3 fatty acids in red blood cell (RBC) membranes |
|
0115T |
Medication therapy management service(s) provided by a pharmacist, individual, face-to-face with patient, initial 15 minutes, with assessment, and intervention if provided; initial encounter |
|
0116T |
Medication therapy management service(s) provided by a pharmacist, individual, face-to-face with patient, initial 15 minutes, with assessment, and intervention if provided; subsequent encounter |
|
0117T |
Medication therapy management service(s) provided by a pharmacist, individual, face-to-face with patient, initial 15 minutes, with assessment, and intervention if provided; each additional 15 minutes (List separately in addition to code for primary service) |
|
0123T |
Fistulization of sclera for glaucoma, through ciliary body |
|
0124T |
Conjunctival incision with posterior juxtascleral placement of pharmacological agent (does not include supply of medication) |
|
0126T |
Common carotid intima-media thickness (IMT) study for evaluation of atherosclerotic burden or coronary heart disease risk factor assessment |
|
0130T |
Validated, statistically reliable, randomized, controlled, single-patient clinical investigation of FDA approved chronic care drugs, provided by a pharmacist, interpretation and report to the prescribing health care professional |
|
0133T |
Upper gastrointestinal endoscopy, including esophagus, stomach, and either the duodenum and/or jejunum as appropriate, with injection of implant material into and along the muscle of the lower esophageal sphincter (eg, for treatment of gastroesophageal reflux disease) |
|
0135T |
Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy |
|
0137T |
Biopsy, prostate, needle, saturation sampling for prostate mapping |
|
0140T |
Exhaled breath condensate Ph |
|
0141T |
Pancreatic islet cell transplantation through portal vein, percutaneous |
|
0142T |
Pancreatic islet cell transplantation through portal vein, open |
|
0143T |
Laparoscopy, surgical, pancreatic islet cell transplantation through portal vein |
|
0144T |
Computed tomography, heart, without contrast material, including image postprocessing and quantitative evaluation of coronary calcium |
|
0153T |
Transcatheter placement of wireless physiologic sensor in aneurysmal sac during endovascular repair, including radiological supervision and interpretation and instrument calibration (List separately in addition to code for primary procedure) |
|
0154T |
Noninvasive physiologic study of implanted wireless pressure sensor in aneurysmal sac following endovascular repair, complete study including recording, analysis of pressure and waveform tracings, interpretation and report |
|
0155T |
Laparoscopy, surgical; implantation or replacement of gastric stimulation electrodes, lesser curvature (ie, morbid obesity) |
|
0156T |
Laparoscopy, surgical; revision or removal of gastric stimulation electrodes, lesser curvature (i.e., morbid obesity) |
|
0157T |
Laparotomy, implantation or replacement of gastric stimulation electrodes, lesser curvature (i.e., morbid obesity) |
|
0158T |
Laparotomy, revision or removal of gastric stimulation electrodes, lesser curvature (i.e., morbid obesity) |
|
0159T |
Computer-aided detection, including computer algorithm analysis of MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation, breast MRI (List separately in addition to code for primary procedure) |
|
0160T |
Therapeutic repetitive transcranial magnetic stimulation treatment planning |
|
0161T |
Therapeutic repetitive transcranial magnetic stimulation treatment delivery and management, per session |
|
0162T |
Electronic analysis and programming, reprogramming of gastric neurostimulator (ie, morbid obesity) |
|
0163T |
Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), lumbar, each additional interspace |
|
0164T |
Removal of total disc arthroplasty, anterior approach, lumbar, each additional interspace |
|
0165T |
Revision of total disc arthroplasty, anterior approach, lumbar, each additional interspace |
|
0166T |
Transmyocardial transcatheter closure of ventricular septal defect, with implant; without cardiopulmonary bypass |
|
0167T |
Transmyocardial transcatheter closure of ventricular septal defect, with implant; with cardiopulmonary bypass |
|
0168T |
Rhinophototherapy, intranasal application of ultraviolet and visible light, bilateral |
|
0169T |
Stereotactic placement of infusion catheter(s) in the brain for delivery of therapeutic agent(s), including computerized stereotactic planning and burr hole(s) |
|
0170T |
Repair of anorectal fistula with plug (e.g., porcine small intestine submucosa [sis1] |
|
0171T |
Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; single level |
|
0172T |
Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; each additional level (List separately in addition to code for primary procedure) |
|
0173T |
Monitoring of intraocular pressure during vitrectomy surgery (List separately in addition to code for primary procedure) |
|
0174T |
Computer aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed concurrent with primary interpretation (List separately in addition to code for primary procedure) |
|
0175T |
Computer aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation |
|
0176T |
Transluminal dilation of aqueous outflow canal; without retention of device or stent |
|
0177T |
Transluminal dilation of aqueous outflow canal; with retention of device or stent |
|
0500F |
Initial prenatal care visit (report at first prenatal encounter with health care professional providing obstetrical care. Report also date of visit and, in a separate field, the date of the last menstrual period-LMP) (Prenatal)2 |
|
0501F |
Prenatal flow sheet documented in medical record by first prenatal visit (documentation includes at minimum blood pressure, weight, urine protein, uterine size, fetal heart tones, and estimated date of delivery). Report also: date of visit and, in a separate field, the date of the last menstrual period - LMP (Note: If reporting 0501F Prenatal flow sheet, it is not necessary to report 0500F Initial prenatal care visit) (Prenatal)1 |
|
0502F |
Subsequent prenatal care visit (Prenatal)2 |
|
0503F |
Postpartum care visit (Prenatal)2 |
|
0505F |
Hemodialysis plan of care documented (ESRD)1 |
|
0507F |
Peritoneal dialysis plan of care documented (ESRD)1 |
|
1000F |
Tobacco use assessed (CAD1, CAP1, COPD1, DM4, PV1) |
|
1002F |
Anginal symptoms and level of activity, assessed (CAD)1 |
|
1003F |
Level of activity assessed (HF)1 |
|
1004F |
Clinical symptoms of volume overload (excess) assessed (HF)1 |
|
1005F |
Asthma symptoms evaluated (includes physician documentation of numeric frequency of symptoms or patient completion of an asthma assessment tool/survey/questionnaire) (Asthma)1 |
|
1006F |
Osteoarthritis symptoms and functional status assessed (may include the use of a standardized scale or the completion of an assessment questionnaire, such as the SF-36, AAOS Hip & Knee Questionnaire) (OA)1 |
|
1007F |
Use of anti-inflammatory or analgesic over-the-counter (OTC) medications for symptom relief assessed (OA) 1 |
|
1008F |
Gastrointestinal and renal risk factors assessed for patients on prescribed or OTC non-steroidal anti-inflammatory drug (NSAID) (OA)1 |
|
1015F |
Chronic obstructive pulmonary disease (COPD) symptoms assessed (Includes assessment of at least one of the following: dyspnea, cough/sputum, wheezing), or respiratory symptom assessment tool completed (COPD)1 |
|
1018F |
Dyspnea assessed, not present (COPD1) |
|
1019F |
Dyspnea assessed, present (COPD1) |
|
1022F |
Pneumococcus immunization status assessed (CAP1, COPD1) |
|
1026F |
Co-morbid conditions assessed (eg, includes assessment for presence or absence of: malignancy, liver disease, congestive heart failure, cerebrovascular disease, renal disease, chronic obstructive pulmonary disease, asthma, diabetes, other co-morbid conditions) (CAP)1 |
|
1030F |
Influenza immunization status assessed (CAP1) |
|
1034F |
Current tobacco smoker (CAD1, CAP1, COPD1, DM4, PV1) |
|
1035F |
Current smokeless tobacco user (e.g., chew, snuff) (PV1) |
|
1036F |
Current tobacco non-user (CAD1, CAP1, COPD1, DM4, PV1) |
|
1038F |
Persistent asthma (mild, moderate or severe) |
|
1039F |
Intermittent asthma |
|
1040F |
DSM-IV™ criteria for major depressive disorder documented (MDD)1 |
|
1050F |
History obtained regarding new or changing moles (ML) |
|
1055F |
Visual functional status assessed (EC) |
|
2000F |
Blood pressure, measured 1 |
|
2001F |
Weight recorded (CHF, PAG) |
|
2002F |
Clinical signs of volume overload (excess) assessed |
|
2004F |
Initial examination of the involved joint(s) (includes visual inspection, palpation, range of motion) (OA)1 |
|
2010F |
Vital signs documented and reviewed (includes at minimum: temperature, pulse, respiration, and blood pressure)(CAP)2 (EM)5 |
|
2014F |
Mental status assessed (CAP)1(EM) 5 |
|
2018F |
Hydration status assessed (normal/mildly dehydrated/severely dehydrated)(CAP1) |
|
2019F |
Dilated macular exam performed, including documentation of the presence or absence of macular thickening or hemorrhage AND the level of macular degeneration severity (EC)5 |
|
2020F |
Dilated fundus evaluation performed within six months prior to cataract surgery (EC)5 |
|
2021F |
Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema AND level of severity of retinopathy (EC)5 |
|
2022F |
Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed (DM)4 |
|
2024F |
Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist documented and reviewed (DM)4 |
|
2026F |
Eye imaging validated to match diagnosis from seven standard field stereoscopic photos results documented and reviewed (DM)4 |
|
2027F |
Optic nerve head evaluation performed (EC)5 |
|
2028F |
Foot examination performed (includes examination through visual inspection, sensory exam with monofilament, and pulse exam - report when any of the three components are completed) (DM)4 |
|
2029F |
Complete physical skin exam performed (ML) |
|
2030F |
Hydration status documented, normally hydrated (PAG)1 |
|
2031F |
Hydration status documented, dehydrated (PAG)1 |
|
3006F |
Chest X-ray results documented and reviewed(CAP1) |
|
3011F |
Lipid panel results documented and reviewed (must include total cholesterol, HDL-C, triglycerides and calculated LDL-C) (CAD)1 |
|
3014F |
Screening mammography results documented and reviewed (PV1) |
|
3017F |
Colorectal cancer screening results documented and reviewed (PV1) |
|
3020F |
Left ventricular function (LVF) assessment (eg, echocardiography, nuclear test, or ventriculography) documented in the medical record (includes: quantitative or qualitative assessment results) (HF)1 |
|
3021F |
Left ventricular ejection fraction (LVEF) < 40% or documentation of moderately or severely depressed left ventricular systolic function (CAD, HF)1 |
|
3022F |
Left ventricular ejection fraction (LVEF) >= 40% or documentation as normal or mildly depressed left ventricular systolic function (CAD, HF)1) |
|
3023F |
Spirometry results documented and reviewed (COPD1) |
|
3025F |
Spirometry test results demonstrate FEV1/FVC < 70% with COPD symptoms (eg, dyspnea, cough/sputum, wheezing) (CAP, COPD)1) |
|
3027F |
Spirometry test results demonstrate FEV1/FVC >= 70% or patient does not have COPD symptoms (COPD)1 |
|
3028F |
Oxygen saturation results documented and reviewed (Includes assessment through pulse oximetry or arterial blood gas measurement) (COPD, CAP)1, (EM)5 |
|
3035F |
Oxygen saturation <= 88 % or a PA02 <= 55 mm hg (COPD1) |
|
3037F |
Oxygen saturation greater than 88% or PAO2 greater than 55 mmhg (COPD1) |
|
3040F |
Functional expiratory volume (FEV1) < 40% of predicted value (COPD)1 |
|
3042F |
Functional expiratory volume (FEV1) >= 40% of predicted value (COPD)1 |
|
3044F |
Most recent hemoglobin A1c level (HbA1c) level < 7.0% (DM)2,4 |
|
3045F |
Most recent hemoglobin A1c (HbA1c) level 7.0 - 9.0 % (DM)2,4 |
|
3046F |
Most recent hemoglobin A1c level > 9.0% (DM)4 |
|
3048F |
Most recent LDL-C < 100 mg/dL (DM)4 |
|
3049F |
Most recent LDL-C 100-129 mg/dL (DM)4 |
|
3050F |
Most recent LDL-C >= 130 mg/dL (DM)4 |
|
3060F |
Positive microalbuminuria test result documented and reviewed (DM)4 |
|
3061F |
Negative microalbuminuria test result documented and reviewed (DM)4 |
|
3062F |
Positive macroalbuminuria test result documented and reviewed (DM)4 |
|
3066F |
Documentation of treatment for nephropathy (eg, patient receiving dialysis, patient being treated for ESRD, CRF, ARF, or renal insufficiency, any visit to a nephrologist) (DM)4 |
|
3072F |
Low risk for retinopathy (no evidence of retinopathy in the prior year) (DM)4 |
|
3073F |
Pre-surgical (cataract) axial length, corneal power measurement and method of intraocular lens power calculation documented within six months prior to surgery (EC)5 |
|
3074F |
Most recent systolic blood pressure < 130 mm Hg (DM)2,4, (HTN)1 |
|
3075F |
Most recent systolic blood pressure 130 - 139mm Hg (DM)2,4, (HTN)1 |
|
3076F |
Most recent systolic blood pressure < 140 mm Hg (DM4 HTN1) |
|
3077F |
Most recent systolic blood pressure >= 140 mm Hg (HTN)1 (DM)4 |
|
3078F |
Most recent diastolic blood pressure < 80 mm Hg (HTN)1 (DM)4 |
|
3079F |
Most recent diastolic blood pressure 80-89 mm Hg (HTN)1 (DM)4 |
|
3080F |
Most recent diastolic blood pressure >= 90 mm Hg (HTN)1 (DM)4 |
|
3082F |
Kt/V <1.2 (Clearance of urea (Kt)/volume (V)) (ESRD)1 |
|
3083F |
Kt/V equal to or greater than 1.2 and less than 1.7 (Clearance of urea (Kt)/volume (V)) (ESRD)1 |
|
3084F |
Kt/V >= 1.7 (Clearance of urea Kt)/volume (V)) (ESRD)1 |
|
3085F |
Suicide risk assessed (MDD)1 |
|
3088F |
Major depressive disorder, mild (MDD)1 |
|
3089F |
Major depressive disorder, moderate (MDD)1 |
|
3090F |
Major depressive disorder, severe without psychotic features (MDD)1 |
|
3091F |
Major depressive disorder, severe with psychotic features (MDD)1 |
|
3092F |
Major depressive disorder, in remission (MDD)1 |
|
3093F |
Documentation of new diagnosis of initial or recurrent episode of major depressive disorder (MDD)1 |
|
3095F |
Central Dual-energy X-Ray Absorptiometry (DXA) results documented (OP)5 |
|
3096F |
Central Dual-energy X-Ray Absorptiometry (DXA) ordered (OP)5 |
|
4000F |
Tobacco use cessation intervention, counseling (COPD, CAP, CAD)1 |
|
4001F |
Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV)1 (DM)4 |
|
4002F |
Statin therapy, prescribed (CAD)1 |
|
4003F |
Patient education, written/oral, appropriate for patients with heart failure, performed (HF)1 |
|
4005F |
Pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed (OP)5 |
|
4006F |
Beta-blocker therapy, prescribed (CAD, HF)1 |
|
4007F |
Age-Related Eye Disease Study (AREDS) formulation prescribed or recommended (EC) (EC)5 |
|
4009F |
Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy, prescribed (HF, CAD)1 |
|
4011F |
Oral antiplatelet therapy prescribed (e.g., aspirin, clopidogrel/Plavix, or combination of aspirin and dipyridamole/Aggrenox) (CAD)1 |
|
4012F |
Warfarin therapy prescribed (CHF)1 |
|
4014F |
Written discharge instructions provided to heart failure patients discharged home. (Instructions include all of the following components: activity level, diet, discharge medications, follow-up appointment, weight monitoring, what to do if symptoms worsen)3 |
|
4015F |
Persistent asthma, preferred long term control medication or an acceptable alternative treatment, prescribed (Asthma)1 |
|
4016F |
Anti-inflammatory/analgesic agent prescribed |
|
4017F |
Gastrointestinal porphylaxis for NSAID use prescribed |
|
4018F |
Therapeutic exercise for the involved joint(s) instructed or physical or occupational therapy prescribed (OA)1 |
|
4019F |
Documentation of receipt of counseling on exercise AND either both calcium and vitamin D use or counseling regarding both calcium and vitamin D use (OP)5 |
|
4025F |
Inhaled bronchodilator prescribed (COPD1) |
|
4030F |
Long-term oxygen therapy prescribed (more than 15 hours per day) (COPD1) |
|
4033F |
Pulmonary rehabilitation exercise training recommended (COPD1) |
|
4035F |
Influenza immunization recommended (COPD1) |
|
4037F |
Influenza immunization ordered or administered (COPD1, PV1) |
|
4040F |
Pneumococcal immunization ordered or administered (COPD1) |
|
4045F |
Appropriate empiric antibiotic prescribed (CAP)1, (EM)5 |
|
4050F |
Hypertension plan of care documented as appropriate (HTN1) |
|
4051F |
Referred for an arterio-venous (AV) fistula (ESRD)1 |
|
4052F |
Hemodialysis via functioning arterio-venous (AV) fistula (ESRD)1 |
|
4053F |
Hemodialysis via functioning arterio-venous (AV) graft (ESRD)1 |
|
4054F |
Hemodialysis via catheter (ESRD)1 |
|
4055F |
Patient receiving peritoneal dialysis (ESRD)1 |
|
4056F |
Appropriate oral rehydration solution recommended (PAG)1 |
|
4058F |
Pediatric gastroenteritis education provided to caregiver (PAG)1 |
|
4060F |
Psychotherapy services provided (MDD)1 |
|
4062F |
Patient referral for psychotherapy documented (MDD)1 |
|
4064F |
Antidepressant pharmacotherapy prescribed (MDD)1 |
|
4065F |
Antipsychotic pharmacotherapy prescribed (MDD)1 |
|
4066F |
Electroconvulsive therapy (ECT) provided (MDD)1 |
|
4067F |
Patient referral for electroconvulsive therapy (ECT) documented (MDD)1 |
|
5005F |
Patient counseled on self-examination for new or changing moles (ML)5 |
|
5010F |
Findings of dilated macular or fundus exam communicated to the physician managing the diabetes care (EC)5 |
|
5015F |
Documentation of communication that a fracture occurred and that the patient was or should be tested or treated for osteoporosis (OP)5 |
|
6005F |
Rationale (e.g., severity of illness and safety) for level of care (e.g., home, hospital) documented (CAP)1 |